Reports Q1 revenue $257,884, consensus $2.63M. Coya‘s CEO commented, “We believe the new data from the IIT trial in patients with FTD and the promising COYA 303 data showing the synergistic potential of low dose IL-2 and GLP-1 RAs has added to the growing evidence that our approach to address Treg dysfunction using combination approaches holds high promise and increases our confidence in the clinical outcomes for COYA-302 in the larger ALS and FTD studies that are planned.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Promising Outlook for Coya Therapeutics: Buy Rating Justified by Innovative Treatments and Pipeline Potential
- Coya Therapeutics reports interim results from IL-2, CTLA4-Ig combination study
- Coya Therapeutics announces publication of study results on COYA 303
- Atea Pharmaceuticals appoints Howard Berman to board of directors
- Coya Therapeutics provides update on exosome platform